Biological
GB226
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_2
4
80%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Other(5)
Detailed Status
unknown5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 24 (80.0%)
Trials by Status
unknown5100%
Recent Activity
0 active trials
Showing 5 of 5
unknownphase_2
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
NCT03639181
unknownphase_1
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
NCT03976856
unknownphase_2
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
NCT03808857
unknownphase_2
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
NCT03502629
unknownphase_2
Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)
NCT03623581
Clinical Trials (5)
Showing 5 of 5 trials
NCT03639181Phase 2
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
NCT03976856Phase 1
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
NCT03808857Phase 2
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
NCT03502629Phase 2
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
NCT03623581Phase 2
Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5